Tessera Therapeutics Showcases New Preclinical Data Demonstrating Progress of In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting
Presented new data in non-human primates (NHP) for sickle cell disease (SCD), where RNA Gene Writer achieved approximately 40% and 60% of long-term hematopoietic stem cells (LT-HSCs) with at least one edited allele after 1 or 2 doses, respectively, exceeding the anticipated curative threshold Evidence in NHP that T cell directed lipid nanoparticles (LNP) produced […]